PALVELLA THERAPEUTICS, INC. (PVLA): restructuring charge — Pieris terminates AstraZeneca deal, cuts 70% workforce, explores strategic alternatives

PALVELLA THERAPEUTICS, INC.

AstraZeneca terminates R&D collaboration effective Oct 15, 2023 due to non-clinical safety findings in elarekibep toxicology study.
Workforce reduced by ~70%; expects ~$3.4M severance costs in Q3 2023.
Cash, equivalents, investments ~$54.9M as of June 30, 2023 (preliminary).
Pieris hires Stifel as financial advisor to explore strategic alternatives including M&A, licensing, or sale.
Focus shifted to advancing cinrebafusp alfa, PRS-220, PRS-400; no assurance of transaction outcome.

item 1.02 item 2.02 item 2.05 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

PALVELLA THERAPEUTICS, INC. announced a restructuring with charges of approximately $3.4 million (approximately 70%).

Type: restructuring
Charge: approximately $3.4 million
Headcount: approximately 70%

Exact text from the filing

on July 17, 2023, the Board of Directors of the Company approved a reduction in force of the Company's workforce by approximately 70% to be substantially completed in the fourth quarter of 2023 (the "Workplace Reduction"). As a result of the Workplace Reduction, the Company expects to incur estimated severance and other employee termination-related costs of approximately $3.4 million in the third quarter 2023.

View on SEC.gov

7 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-020094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.